O	0	5	Phase
O	6	9	III
O	10	20	randomized
O	21	26	trial
O	27	29	of
B-intervention	30	41	doxorubicin
I-intervention	42	45	and
I-intervention	46	55	docetaxel
O	56	62	versus
B-control	63	74	doxorubicin
I-control	75	78	and
I-control	79	95	cyclophosphamide
O	96	98	as
O	99	106	primary
O	107	114	medical
O	115	122	therapy
O	123	125	in
O	126	131	women
O	132	136	with
O	137	143	breast
O	144	150	cancer
O	150	151	:
O	152	154	an
O	155	160	anglo
O	160	161	-
O	161	167	celtic
O	168	179	cooperative
O	180	188	oncology
O	189	194	group
O	195	200	study
O	200	201	.

O	202	209	PURPOSE
O	210	212	To
O	213	220	compare
O	221	224	the
O	225	233	clinical
O	234	237	and
O	238	248	pathologic
O	249	257	response
O	258	263	rates
O	264	266	of
O	267	278	doxorubicin
O	279	282	and
O	283	299	cyclophosphamide
O	300	301	(
O	301	303	AC
O	303	304	)
O	305	309	with
O	310	321	doxorubicin
O	322	325	and
O	326	335	docetaxel
O	336	337	(
O	337	339	AD
O	339	340	)
O	341	343	as
O	344	351	primary
O	352	364	chemotherapy
O	365	367	in
B-eligibility	368	373	women
I-eligibility	374	378	with
I-eligibility	379	386	primary
I-eligibility	387	389	or
I-eligibility	390	397	locally
I-eligibility	398	406	advanced
I-eligibility	407	413	breast
I-eligibility	414	420	cancer
O	420	421	.

O	422	430	PATIENTS
O	431	434	AND
O	435	442	METHODS
O	443	451	Eligible
O	452	460	patients
O	461	465	with
O	466	480	histologically
O	481	487	proven
O	488	494	breast
O	495	501	cancer
O	502	506	with
O	507	514	primary
O	515	521	tumors
O	522	523	>
O	523	524	/
O	524	525	=
O	526	527	3
O	528	530	cm
O	530	531	,
O	532	544	inflammatory
O	545	547	or
O	548	555	locally
O	556	564	advanced
O	565	572	disease
O	572	573	,
O	574	577	and
O	578	580	no
O	581	589	evidence
O	590	592	of
O	593	603	metastases
O	604	608	were
O	609	617	randomly
O	618	626	assigned
O	627	629	to
O	630	637	receive
O	638	639	a
O	640	647	maximum
O	648	650	of
O	651	654	six
O	655	661	cycles
O	662	664	of
O	665	671	either
O	672	683	doxorubicin
O	684	685	(
O	685	687	60
O	688	690	mg
O	690	691	/
O	691	692	m
O	692	693	(
O	693	694	2
O	694	695	)
O	695	696	)
O	697	701	plus
O	702	718	cyclophosphamide
O	719	720	(
O	720	723	600
O	724	726	mg
O	726	727	/
O	727	728	m
O	728	729	(
O	729	730	2
O	730	731	)
O	731	732	)
O	733	745	administered
O	746	759	intravenously
O	760	761	(
O	761	763	IV
O	763	764	)
O	765	770	every
O	771	772	3
O	773	778	weeks
O	779	781	or
O	782	793	doxorubicin
O	794	795	(
O	795	797	60
O	798	800	mg
O	800	801	/
O	801	802	m
O	802	803	(
O	803	804	2
O	804	805	)
O	805	806	)
O	807	811	plus
O	812	821	docetaxel
O	822	823	(
O	823	825	75
O	826	828	mg
O	828	829	/
O	829	830	m
O	830	831	(
O	831	832	2
O	832	833	)
O	833	834	)
O	835	837	IV
O	838	843	every
O	844	845	3
O	846	851	weeks
O	851	852	,
O	853	861	followed
O	862	864	by
O	865	872	surgery
O	873	875	on
O	876	886	completion
O	887	889	of
O	890	902	chemotherapy
O	902	903	.

O	904	911	Results
O	912	913	A
O	914	919	total
O	920	922	of
B-total-participants	923	926	363
O	927	935	patients
O	936	940	were
O	941	949	randomly
O	950	958	assigned
O	959	961	to
O	962	964	AC
O	965	966	(
O	966	967	n
O	968	969	=
B-intervention-participants	970	973	180
O	973	974	)
O	975	977	or
O	978	980	AD
O	981	982	(
O	982	983	n
O	984	985	=
B-control-participants	986	989	183
O	989	990	)
O	990	991	.

O	992	993	A
B-outcome	994	1002	complete
I-outcome	1003	1011	clinical
I-outcome	1012	1020	response
O	1021	1024	was
O	1025	1033	observed
O	1034	1036	in
B-iv-bin-percent	1037	1039	17
I-iv-bin-percent	1039	1040	%
O	1041	1044	and
B-cv-bin-percent	1045	1047	20
I-cv-bin-percent	1047	1048	%
O	1049	1051	of
O	1052	1060	patients
O	1061	1068	treated
O	1069	1073	with
O	1074	1076	AC
O	1077	1080	and
O	1081	1083	AD
O	1083	1084	,
O	1085	1097	respectively
O	1098	1099	(
O	1099	1100	P
O	1101	1102	=
O	1103	1104	.
O	1104	1106	42
O	1106	1107	)
O	1107	1108	.

B-outcome	1109	1116	Overall
I-outcome	1117	1118	(
I-outcome	1118	1126	complete
I-outcome	1127	1130	and
I-outcome	1131	1138	partial
I-outcome	1138	1139	)
I-outcome	1140	1148	clinical
I-outcome	1149	1157	response
I-outcome	1158	1163	rates
O	1164	1167	for
O	1168	1170	AC
O	1171	1174	and
O	1175	1177	AD
O	1178	1182	were
B-iv-bin-percent	1183	1185	61
I-iv-bin-percent	1185	1186	%
O	1187	1190	and
B-cv-bin-percent	1191	1193	70
I-cv-bin-percent	1193	1194	%
O	1194	1195	,
O	1196	1208	respectively
O	1209	1210	(
O	1210	1211	P
O	1212	1213	=
O	1214	1215	.
O	1215	1217	06
O	1217	1218	)
O	1218	1219	.

O	1220	1225	There
O	1226	1229	was
O	1230	1232	no
O	1233	1244	significant
O	1245	1255	difference
O	1256	1258	in
O	1259	1265	either
O	1266	1269	the
O	1270	1280	pathologic
B-outcome	1281	1289	complete
I-outcome	1290	1298	response
I-outcome	1299	1304	rates
O	1305	1307	in
O	1308	1311	the
O	1312	1318	breast
O	1319	1323	with
O	1324	1326	AC
O	1327	1328	(
B-iv-bin-percent	1328	1330	24
I-iv-bin-percent	1330	1331	%
O	1331	1332	)
O	1333	1336	and
O	1337	1339	AD
O	1340	1341	(
B-cv-bin-percent	1341	1343	21
I-cv-bin-percent	1343	1344	%
O	1344	1345	;
O	1346	1347	P
O	1348	1349	=
O	1350	1351	.
O	1351	1353	61
O	1353	1354	)
O	1355	1357	or
O	1358	1360	in
O	1361	1364	the
B-outcome	1365	1371	number
I-outcome	1372	1374	of
I-outcome	1375	1383	patients
I-outcome	1384	1388	with
I-outcome	1389	1397	positive
I-outcome	1398	1406	axillary
I-outcome	1407	1412	nodes
I-outcome	1413	1415	at
I-outcome	1416	1423	surgery
O	1424	1428	with
O	1429	1431	AC
O	1432	1433	(
B-iv-bin-percent	1433	1435	61
I-iv-bin-percent	1435	1436	%
O	1436	1437	)
O	1438	1441	and
O	1442	1444	AD
O	1445	1446	(
B-cv-bin-percent	1446	1448	66
I-cv-bin-percent	1448	1449	%
O	1449	1450	;
O	1451	1452	P
O	1453	1454	=
O	1455	1456	.
O	1456	1458	28
O	1458	1459	)
O	1459	1460	.

O	1461	1463	At
O	1464	1465	a
O	1466	1472	median
O	1473	1479	follow
O	1479	1480	-
O	1480	1482	up
O	1483	1485	of
O	1486	1488	32
O	1489	1495	months
O	1495	1496	,
O	1497	1502	there
O	1503	1505	is
O	1506	1508	no
O	1509	1520	significant
O	1521	1531	difference
O	1532	1539	between
O	1540	1543	the
O	1544	1547	two
O	1548	1554	groups
O	1555	1558	for
O	1559	1562	the
B-outcome	1563	1569	number
I-outcome	1570	1572	of
I-outcome	1573	1581	relapses
O	1581	1582	.

O	1583	1593	CONCLUSION
O	1594	1596	In
O	1597	1605	contrast
O	1606	1608	to
O	1609	1612	the
O	1613	1621	positive
O	1622	1629	results
O	1630	1638	reported
O	1639	1642	for
O	1643	1653	sequential
O	1654	1663	docetaxel
O	1664	1669	after
O	1670	1672	AC
O	1673	1675	as
O	1676	1683	primary
O	1684	1696	chemotherapy
O	1697	1699	of
O	1700	1706	breast
O	1707	1713	cancer
O	1713	1714	,
O	1715	1718	our
O	1719	1723	data
O	1724	1726	do
O	1727	1730	not
O	1731	1738	suggest
O	1739	1740	a
O	1741	1748	benefit
O	1749	1752	for
O	1753	1765	simultaneous
O	1766	1768	AD
O	1769	1773	over
O	1774	1776	AC
O	1776	1777	.
